1
|
Chang Z, Wang W, Huang Z, Huang Y, Wu C, Pan X. Lecithin Reverse Micelle System is Promising in Constructing Carrier Particles for Protein Drugs Encapsulated Pressurized Metered‐Dose Inhalers. ADVANCED THERAPEUTICS 2023; 6. [DOI: 10.1002/adtp.202300046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2023] [Indexed: 06/25/2024]
Abstract
AbstractProtein drugs contained within pressurized metered dose inhalers (pMDIs) show immense potential for fundamental research and industrial applications, owing to their high bioavailability, convenient administration, and cost‐effectiveness. To deliver protein drugs efficiently, researchers have reached a consensus on the use of carrier particles. However, the main obstacle impeding the commercial availability of pMDI carrier particles is their low stability. This instability is primarily attributed to particle aggregation caused by the Ostwald ripening phenomenon and chemical degradation by water sensitivity of protein drugs. This study proposes the utilization of lecithin, a carrier material possessing an amphiphilic structure, to overcome this bottleneck. By constructing lecithin‐based reverse micelle systems with protein drugs encapsulated within the high‐polarity microdomain, this work anticipates an improvement in the stability of carrier particles within pMDIs. Specifically, the formation of crystalline phases in the reverse micelle systems can control carrier particle size through crystalline self‐limiting effect, preventing particle aggregation. Additionally, the low‐polarity microdomain of the carrier serves as a hydrophobic barrier, shielding protein drugs from water and preventing chemical degradation. Consequently, this work believes that the lecithin‐based reverse micelle system holds significant potential in providing new theoretical insights and experimental support for the advancement of pMDIs containing protein drugs.
Collapse
Affiliation(s)
- Ziyao Chang
- School of Pharmaceutical Sciences Sun Yat‐Sen University Guangzhou Guangdong 510006 P. R. China
| | - Wenhao Wang
- School of Pharmaceutical Sciences Sun Yat‐Sen University Guangzhou Guangdong 510006 P. R. China
| | - Zhengwei Huang
- College of Pharmacy Jinan University Guangzhou Guangdong 511443 P. R. China
| | - Ying Huang
- College of Pharmacy Jinan University Guangzhou Guangdong 511443 P. R. China
| | - Chuanbin Wu
- College of Pharmacy Jinan University Guangzhou Guangdong 511443 P. R. China
| | - Xin Pan
- School of Pharmaceutical Sciences Sun Yat‐Sen University Guangzhou Guangdong 510006 P. R. China
| |
Collapse
|
2
|
Tundisi LL, Ataide JA, Costa JSR, Coêlho DDF, Liszbinski RB, Lopes AM, Oliveira-Nascimento L, de Jesus MB, Jozala AF, Ehrhardt C, Mazzola PG. Nanotechnology as a tool to overcome macromolecules delivery issues. Colloids Surf B Biointerfaces 2023; 222:113043. [PMID: 36455361 DOI: 10.1016/j.colsurfb.2022.113043] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2022] [Revised: 11/09/2022] [Accepted: 11/18/2022] [Indexed: 11/21/2022]
Abstract
Nanocarriers can deliver drugs to specific organs or cells, potentially bridging the gap between a drug's function and its interaction with biological systems such as human physiology. The untapped potential of nanotechnology stems from its ability to manipulate materials, allowing control over physical and chemical properties and overcoming drug-related problems, e.g., poor solubility or poor bioavailability. For example, most protein drugs are administered parenterally, each with challenges and peculiarities. Some problems faced by bioengineered macromolecule drugs leading to poor bioavailability are short biological half-life, large size and high molecular weight, low permeability through biological membranes, and structural instability. Nanotechnology emerges as a promising strategy to overcome these problems. Nevertheless, the delivery system should be carefully chosen considering loading efficiency, physicochemical properties, production conditions, toxicity, and regulations. Moving from the bench to the bedside is still one of the major bottlenecks in nanomedicine, and toxicological issues are the greatest challenges to overcome. This review provides an overview of biotech drug delivery approaches, associated nanotechnology novelty, toxicological issues, and regulations.
Collapse
Affiliation(s)
| | - Janaína Artem Ataide
- Faculty of Pharmaceutical Sciences, University of Campinas (Unicamp), Campinas, Brazil.
| | - Juliana Souza Ribeiro Costa
- Faculty of Pharmaceutical Sciences, University of Campinas (Unicamp), Campinas, Brazil; Laboratory of Pharmaceutical Technology (Latef), Faculty of Pharmaceutical Sciences, University of Campinas (Unicamp), Campinas, Brazil
| | | | - Raquel Bester Liszbinski
- Nano-Cell Interactions Lab., Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas (Unicamp), Campinas, Brazil
| | - André Moreni Lopes
- Faculty of Pharmaceutical Sciences, University of Campinas (Unicamp), Campinas, Brazil
| | - Laura Oliveira-Nascimento
- Faculty of Pharmaceutical Sciences, University of Campinas (Unicamp), Campinas, Brazil; Laboratory of Pharmaceutical Technology (Latef), Faculty of Pharmaceutical Sciences, University of Campinas (Unicamp), Campinas, Brazil
| | - Marcelo Bispo de Jesus
- Nano-Cell Interactions Lab., Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas (Unicamp), Campinas, Brazil
| | - Angela Faustino Jozala
- LAMINFE - Laboratory of Industrial Microbiology and Fermentation Process, University of Sorocaba, Sorocaba, Brazil
| | - Carsten Ehrhardt
- School of Pharmacy and Pharmaceutical Sciences and Trinity Biomedical Sciences Institute Trinity College Dublin, Dublin, Ireland
| | - Priscila Gava Mazzola
- Faculty of Pharmaceutical Sciences, University of Campinas (Unicamp), Campinas, Brazil
| |
Collapse
|
3
|
Hou S, Wu J, Li X, Shu H. Practical, regulatory and clinical considerations for development of inhalation drug products. Asian J Pharm Sci 2015. [DOI: 10.1016/j.ajps.2015.08.008] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
4
|
Myrdal PB, Sheth P, Stein SW. Advances in metered dose inhaler technology: formulation development. AAPS PharmSciTech 2014; 15:434-55. [PMID: 24452499 DOI: 10.1208/s12249-013-0063-x] [Citation(s) in RCA: 101] [Impact Index Per Article: 10.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2013] [Accepted: 11/15/2013] [Indexed: 12/20/2022] Open
Abstract
Pressurized metered dose inhalers (MDIs) are a long-standing method to treat diseases of the lung, such as asthma and chronic obstructive pulmonary disease. MDIs rely on the driving force of the propellant, which comprises the bulk of the MDI formulation, to atomize droplets containing drug and excipients, which ideally should deposit in the lungs. During the phase out of chlorofluorocarbon propellants and the introduction of more environmentally friendly hydrofluoroalkane propellants, many improvements were made to the methods of formulating for MDI drug delivery along with a greater understanding of formulation variables on product performance. This review presents a survey of challenges associated with formulating MDIs as solution or suspension products with one or more drugs, while considering the physicochemical properties of various excipients and how the addition of these excipients may impact overall product performance of the MDI. Propellants, volatile and nonvolatile cosolvents, surfactants, polymers, suspension stabilizers, and bulking agents are among the variety of excipients discussed in this review article. Furthermore, other formulation approaches, such as engineered excipient and drug-excipient particles, to deliver multiple drugs from a single MDI are also evaluated.
Collapse
|
5
|
Myrdal PB, Sheth P, Stein SW. Advances in metered dose inhaler technology: formulation development. AAPS PharmSciTech 2014. [PMID: 24452499 DOI: 10.1208/s12249-013-0063-x.] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
Pressurized metered dose inhalers (MDIs) are a long-standing method to treat diseases of the lung, such as asthma and chronic obstructive pulmonary disease. MDIs rely on the driving force of the propellant, which comprises the bulk of the MDI formulation, to atomize droplets containing drug and excipients, which ideally should deposit in the lungs. During the phase out of chlorofluorocarbon propellants and the introduction of more environmentally friendly hydrofluoroalkane propellants, many improvements were made to the methods of formulating for MDI drug delivery along with a greater understanding of formulation variables on product performance. This review presents a survey of challenges associated with formulating MDIs as solution or suspension products with one or more drugs, while considering the physicochemical properties of various excipients and how the addition of these excipients may impact overall product performance of the MDI. Propellants, volatile and nonvolatile cosolvents, surfactants, polymers, suspension stabilizers, and bulking agents are among the variety of excipients discussed in this review article. Furthermore, other formulation approaches, such as engineered excipient and drug-excipient particles, to deliver multiple drugs from a single MDI are also evaluated.
Collapse
Affiliation(s)
- Paul B Myrdal
- College of Pharmacy, University of Arizona, 1703 E. Mabel St., PO Box 210207, Tucson, Arizona, 85721, USA,
| | | | | |
Collapse
|
6
|
Osman R, Al Jamal KT, Kan PL, Awad G, Mortada N, El-Shamy AE, Alpar O. Inhalable DNase I microparticles engineered with biologically active excipients. Pulm Pharmacol Ther 2013; 26:700-9. [PMID: 23933140 DOI: 10.1016/j.pupt.2013.07.010] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/20/2013] [Revised: 07/29/2013] [Accepted: 07/30/2013] [Indexed: 12/23/2022]
Abstract
Highly viscous mucus poses a big challenge for the delivery of particulates carrying therapeutics to patients with cystic fibrosis. In this study, surface modifying DNase I loaded particles using different excipients to achieve better lung deposition, higher enzyme stability or better biological activity had been exploited. For the purpose, controlled release microparticles (MP) were prepared by co-spray drying DNase I with the polymer poly-lactic-co-glycolic acid (PLGA) and the biocompatible lipid surfactant 1,2-dipalmitoyl-Sn-phosphatidyl choline (DPPC) using various hydrophilic excipients. The effect of the included modifiers on the particle morphology, size, zeta potential as well as enzyme encapsulation efficiency, biological activity and release had been evaluated. Powder aerosolisation performance and particle phagocytosis by murine macrophages were also investigated. The results showed that more than 80% of enzyme activity was recovered after MP preparation and that selected surface modifiers greatly increased the enzyme encapsulation efficiency. The particle morphology was greatly modified altering in turn the powders inhalation indices where dextran, ovalbumin and chitosan hydrochloride increased considerably the respirable fraction compared to the normal hydrophilic carriers lactose and PVP. Despite of the improved aerosolisation caused by chitosan hydrochloride, yet retardation of chitosan coated particles in artificial mucus samples discouraged its application. On the other hand, dextran and polyanions enhanced DNase I effect in reducing cystic fibrosis mucus viscosity. DPPC proved good ability to reduce particles phagocytic uptake even in the presence of the selected adjuvants. The prepared MP systems were biocompatible with lung epithelial cells. To conclude, controlled release DNase I loaded PLGA-MP with high inhalation indices and enhanced mucolytic activity on CF sputum could be obtained by surface modifying the particles with PGA or dextran.
Collapse
Affiliation(s)
- Rihab Osman
- UCL-School of Pharmacy, London University, 29-39 Brunswick Square, London WC1N1AX, UK; Faculty of Pharmacy, Ain Shams University, P.O. Box:11566, Cairo, Egypt.
| | | | | | | | | | | | | |
Collapse
|
7
|
Haddrell AE, Hargreaves G, Davies JF, Reid JP. Control over hygroscopic growth of saline aqueous aerosol using Pluronic polymer additives. Int J Pharm 2013; 443:183-92. [PMID: 23333755 DOI: 10.1016/j.ijpharm.2012.12.039] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2012] [Revised: 12/19/2012] [Accepted: 12/20/2012] [Indexed: 11/30/2022]
Abstract
The hygroscopic properties of an aerosol originating from a nebulizer solution can affect the extent of peripheral deposition within the respiratory tract, which in turn affects drug efficacy of drugs delivered to the lungs. Thus, the ability to tailor the degree and rate of hygroscopic growth of an aerosol produced by a nebulizer through modification of the formulation would serve to improve drug efficacy through targeted lung deposition. In this study, the kinetic and thermodynamic hygroscopic properties of sodium chloride aerosol mixed with commercially available Pluronic polymers, specifically F77 and F127, are reported using three complementary single aerosol analysis techniques, specifically aerosol optical tweezers, a double ring electrodynamic balance and a concentric cylinder electrodynamic balance. The F77 polymer is shown to have a predictable effect on the hygroscopic properties of the aerosol: the ability of the droplet to uptake water from the air depends on the solute weight percent of sodium chloride present in a linear dose dependant manner. Unlike the smaller F77, a non-linear relationship was observed for the larger molecular weight F127 polymer, with significant suppression of hygroscopic growth (>50% by mass) for solution aerosol containing even only 1 wt% of the polymer and 99 wt% sodium chloride. The suppression of growth is shown to be consistent with the formation of mixed phase aerosol particles containing hydrophilic inorganic rich domains and hydrophobic polymer rich domains that sequester some of the inorganic component, with the two phases responding to changes in relative humidity independently. This independence of coupling with the gas phase is apparent in both the equilibrium state and the kinetics of water evaporation/condensation. By starting with a saline nebulizer solution with a concentration of F127 ∼10(-2)mM, a 12% reduction in the radius of all aerosol produced at a relative humidity (RH) of 84% is possible. The difference in diameter is RH dependent, and may be much greater at higher humidities. These findings suggest that the addition of μM concentrations of larger Pluronic polymers to nebulizer formulations may greatly reduce the size of aerosols produced.
Collapse
|
8
|
Wu L, da Rocha SRP. Nanoparticle-stabilized colloids in compressible hydrofluoroalkanes. LANGMUIR : THE ACS JOURNAL OF SURFACES AND COLLOIDS 2011; 27:10501-10506. [PMID: 21774500 DOI: 10.1021/la201906f] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
In this work, we show that nanoparticles (NPs) dispersed in compressible hydrofluoroalkanes (HFAs) at small volume fractions are capable of stabilizing micrometer-sized particle colloids, which otherwise flocculate due to strong van der Waals forces. Water-soluble, biodegradable NPs with a chitosan (CS) core, grafted with highly HFA-philic moieties, can be readily dispersed in the low dielectric HFAs and are capable of imparting stability to a wide range of therapeutic particles having different chemistries (polar or hydrophobic; small and large molecular weight, including peptides and proteins) and morphologies (micronized crystals or amorphous). These NP systems thus serve as a broadly applicable platform for the noninvasive delivery of therapeutics to and through the lungs using propellant-based, portable inhalers, and are also of potential relevance in other industries where HFAs are employed as solvents or propellants. This concept may also be applicable to other compressible solvents.
Collapse
Affiliation(s)
- Libo Wu
- Department of Chemical Engineering and Materials Science, Wayne State University, Detroit, Michigan 48202, USA
| | | |
Collapse
|
9
|
Traynor MJ, Zhao Y, Brown MB, Jones SA. Vinyl polymer-coated lorazepam particles for drug delivery to the airways. Int J Pharm 2011; 410:9-16. [DOI: 10.1016/j.ijpharm.2011.02.053] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2010] [Revised: 02/21/2011] [Accepted: 02/23/2011] [Indexed: 10/18/2022]
|
10
|
Enhanced properties of discrete pulmonary deoxyribonuclease I (DNaseI) loaded PLGA nanoparticles during encapsulation and activity determination. Int J Pharm 2011; 408:257-65. [DOI: 10.1016/j.ijpharm.2011.02.013] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2010] [Revised: 02/05/2011] [Accepted: 02/08/2011] [Indexed: 10/18/2022]
|
11
|
Rosner K, Kasprzak MF, Horenstein ACJ, Thurston HL, Abrams J, Kerwin LY, Mehregan DA, Mehregan DR. Engineering a waste management enzyme to overcome cancer resistance to apoptosis: adding DNase1 to the anti-cancer toolbox. Cancer Gene Ther 2011; 18:346-57. [PMID: 21233855 DOI: 10.1038/cgt.2010.84] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
Cancer treatment is often complicated by resistance to conventional anti-cancer treatment and to more recently developed immunotherapy and gene therapy. These therapeutic modalities aim at activating death pathways within cancer cells. Attempts to activate the apoptotic death pathway, by overexpressing proapoptotic signals, are compromised by cancer defense mechanisms, which disrupt the apoptotic-signaling cascade downstream of the overexpressed component. Here, we describe a therapeutic option of triggering apoptosis without activating the apoptotic-signaling cascade or using the native apoptosis executioner nuclease. We have engineered Deoxyribonuclease-1 (DNase1), a waste-management enzyme, by deleting its signal peptide, adding a nuclear localization signal, and mutating its actin-binding site. Apoptosis studies and colony-forming assay for assessing cell viability were conducted in apoptosis-resistant Mel-Juso human melanoma cells. The modified DNase1 reduced cell viability by 77% relative to controls. It also induced typical microscopic features of cellular apoptosis, such as Terminal Transferase dUTP Nick-End Labeling-positive cells and DNA fragmentation. Quantification of apoptosis by Laser scanning cytometry demonstrated high-killing efficiency of 70-100%. The results suggest that this modified DNase1 can efficiently eliminate apoptosis-resistant cancer cells through apoptosis. Coupled to different tissue-specific gene expression elements, this recombinant DNase1 may serve as a platform for eliminating a variety of cancer types.
Collapse
Affiliation(s)
- K Rosner
- Laboratory for Molecular Dermatology, Program in Molecular Biology and Genetics, Barbara Ann Karmanos Cancer Institute, Detroit, MI 48201, USA.
| | | | | | | | | | | | | | | |
Collapse
|
12
|
Li HY, Song X, Seville PC. The use of sodium carboxymethylcellulose in the preparation of spray-dried proteins for pulmonary drug delivery. Eur J Pharm Sci 2010; 40:56-61. [PMID: 20188824 DOI: 10.1016/j.ejps.2010.02.007] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2009] [Revised: 02/01/2010] [Accepted: 02/19/2010] [Indexed: 10/19/2022]
Abstract
The use of sodium carboxymethylcellulose (NaCMC) as a spray-drying excipient in the preparation of inhalable formulations of proteins was investigated, using alkaline phosphatase as a model functional protein. Two spray-dried powders were investigated: a control powder comprising 100% (w/w) alkaline phosphatase and a test powder comprising 67% (w/w) NaCMC and 33% (w/w) alkaline phosphatase. Following physicochemical characterisation, the powders were prepared as both dry powder inhaler (DPI) and pressurised metered dose inhaler (pMDI) formulations. The aerosolisation performance of the formulations was assessed using a Multi-Stage Liquid Impinger, both immediately after preparation and over a 16-week storage period. Formulating the control powder as a DPI resulted in a poor fine particle fraction (FPF: 10%), whereas the FPF of the NaCMC-modified DPI formulation was significantly greater (47%). When the powders were formulated as pMDI systems, the control and NaCMC-modified powders demonstrated FPFs of 52% and 55%, respectively. Following storage, reduced FPF was observed for all formulations except the NaCMC-modified pMDI system; the performance of this formulation following storage was statistically equivalent to that immediately following preparation. Co-spray-drying proteins and peptides with NaCMC may therefore offer an alternative method for the preparation of stable and respirable pMDI formulations for pulmonary delivery.
Collapse
Affiliation(s)
- Hao-Ying Li
- School of Life and Health Sciences, Aston University, Birmingham B4 7ET, UK
| | | | | |
Collapse
|
13
|
Li HY, Seville PC. Novel pMDI formulations for pulmonary delivery of proteins. Int J Pharm 2009; 385:73-8. [PMID: 19854252 DOI: 10.1016/j.ijpharm.2009.10.032] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2009] [Revised: 10/09/2009] [Accepted: 10/14/2009] [Indexed: 11/15/2022]
Abstract
In this paper, we demonstrate that co-spray-drying a model protein with sodium carboxymethylcellulose (NaCMC) protects protein integrity during spray-drying, and that the resultant spray-dried powders can be successfully dispersed in hydrofluoroalkane (HFA) propellant to prepare pressurised metered dose (pMDI) formulations that exhibit high respirable fractions. The spray-dried powders were formulated as HFA-134a pMDI suspensions in the absence of any other excipients (e.g. surfactants) or co-solvents (e.g. ethanol). The in vitro aerosolisation profile of these systems was assessed using the twin stage impinger; fine particle fractions (FPF) > or = 50% of the recovered dose were obtained. Following storage for five months, the aerosolisation performance was reassessed; the NaCMC-free formulation demonstrated a significant decrease in FPF, whereas the performance of the NaCMC-modified formulations was statistically equivalent to their initial performance. Thus, formulation of pMDI suspensions using NaCMC-based spray-dried powders is a promising approach for the pulmonary delivery of proteins and peptides.
Collapse
Affiliation(s)
- Hao-Ying Li
- School of Life and Health Sciences, Aston University, Aston Triangle, Birmingham B4 7ET, UK
| | | |
Collapse
|
14
|
Peguin RPS, Kamath G, Potoff JJ, da Rocha SRP. All-Atom Force Field for the Prediction of Vapor−Liquid Equilibria and Interfacial Properties of HFA134a. J Phys Chem B 2008; 113:178-87. [DOI: 10.1021/jp806213w] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Affiliation(s)
- Robson P. S. Peguin
- Department of Chemical Engineering and Materials Science, Wayne State University, 5050 Anthony Wayne Drive, Detroit, Michigan 48202
| | - Ganesh Kamath
- Department of Chemical Engineering and Materials Science, Wayne State University, 5050 Anthony Wayne Drive, Detroit, Michigan 48202
| | - Jeffrey J. Potoff
- Department of Chemical Engineering and Materials Science, Wayne State University, 5050 Anthony Wayne Drive, Detroit, Michigan 48202
| | - Sandro R. P. da Rocha
- Department of Chemical Engineering and Materials Science, Wayne State University, 5050 Anthony Wayne Drive, Detroit, Michigan 48202
| |
Collapse
|
15
|
Liu XB, Ye JX, Quan LH, Liu CY, Deng XL, Yang M, Liao YH. Pulmonary delivery of scutellarin solution and mucoadhesive particles in rats. Eur J Pharm Biopharm 2008; 70:845-52. [DOI: 10.1016/j.ejpb.2008.07.004] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2008] [Revised: 06/26/2008] [Accepted: 07/03/2008] [Indexed: 10/21/2022]
|
16
|
Buttini F, Colombo P, Wenger MPE, Mesquida P, Marriott C, Jones SA. Back to basics: the development of a simple, homogenous, two-component dry-powder inhaler formulation for the delivery of budesonide using miscible vinyl polymers. J Pharm Sci 2008; 97:1257-67. [PMID: 17680663 DOI: 10.1002/jps.21126] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
It was hypothesised that formulating a dry-powder inhaler (DPI) using a refined, smooth grade of lactose, without fines and a polymer coated drug microparticle should produce an homogeneous formulation in which aerosolization behaviour could be modified. Hence, the aim of this study was to develop a simple two component polymer coated-budesonide/lactose blend in which the drug microparticle adhesive forces could be optimised by modifying the drug coating in order to improve aerosolization from a DPI. Budesonide microparticles (1.83 +/- 0.03 microm) were coated with the vinyl polymers by adsorption and then spray-dried. The drug was blended with three different types of lactose, checked for uniformity of mixing and loaded into Pulvinal devices. The median volume particle size of all but one of the polymer coated microparticles remained below 4 microm after spray-drying and the content uniformity for all the blends >96%. Coating the budesonide with 0.01% poly(vinyl alcohol) increased the fine particle fraction (FPF) in the next generation impactor (NGI) from 29.1 +/- 0.7% to 52.8 +/- 1.0% and reduced the force of adhesion from 410 +/- 182 to 241 +/- 82 nN with smooth lactose. This illustrates that vinyl polymers could effectively modify adhesive interactions without the need for ternary components such as fines.
Collapse
Affiliation(s)
- F Buttini
- Department of Pharmacy, University of Parma, Area delle Scienze, 43100 Parma, Italy
| | | | | | | | | | | |
Collapse
|
17
|
Wu L, da Rocha SRP. Biocompatible and biodegradable copolymer stabilizers for hydrofluoroalkane dispersions: a colloidal probe microscopy investigation. LANGMUIR : THE ACS JOURNAL OF SURFACES AND COLLOIDS 2007; 23:12104-12110. [PMID: 17958454 DOI: 10.1021/la702108x] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
In this work we investigate the ability of biodegradable and biocompatible lactide-based nonionic amphiphiles to stabilize a model drug (salbutamol base) dispersion in hydrofluoroalkane (HFA) propellant. A series of triblock copolymers of the type poly(lactide)-poly(ethylene glycol)-poly(lactide) (LA(m)EO(n)LA(m)) with varying molecular weight (MW) and % EO were synthesized. The cohesive forces between drug particles in liquid HFA in the presence of the amphiphiles were quantitatively determined by colloidal probe microscopy (CPM). The effect of cosolvent, oleic acid, and a nonionic triblock copolymer with the propylene oxide moiety as the HFA-phile was also investigated. CPM results show that the overall concentration, MW, surfactant tail (LA) length, and the ratio between the stabilizing LA moiety and the anchor EO group have a great impact on the drug cohesive forces. The CPM results in liquid HFA were correlated to the bulk physical stability of the drug suspensions in the propellant 1,1,1,2,3,3,3-heptafluoropropane (HFA227). The dispersions in HFA227 were significantly improved in the presence of LA(m)EO(n)LA(m), correlating well with the low cohesive forces determined by CPM. The applicability of LA-based amphiphiles might be extended to other suspension-based formulations provided a suitable headgroup is found. This study is relevant for the development of HFA-based dispersion pressurized metered-dose inhaler formulations.
Collapse
Affiliation(s)
- Libo Wu
- Department of Chemical Engineering and Materials Science, Wayne State University, Detroit, MI 48202, USA
| | | |
Collapse
|
18
|
Wu L, Al-Haydari M, da Rocha SRP. Novel propellant-driven inhalation formulations: engineering polar drug particles with surface-trapped hydrofluoroalkane-philes. Eur J Pharm Sci 2007; 33:146-58. [PMID: 18083015 DOI: 10.1016/j.ejps.2007.10.007] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2007] [Revised: 10/29/2007] [Accepted: 10/30/2007] [Indexed: 10/22/2022]
Abstract
Challenges in reformulating pressurized metered-dose inhalers (pMDIs) with hydrofluoroalkane (HFA) propellants, and the potential of inhalation formulations for the delivery of drugs to and through the lungs have encouraged the development of novel suspension-based pMDI formulations. In this work we propose a new methodology for engineering polar drug particles with enhanced stability and aerosol characteristics in propellant HFAs. The approach consists in 'trapping' HFA-philic moieties at the surface of particles, which are formed using a modified emulsification-diffusion method. The trapped moieties act as stabilizing agents, thus preventing flocculation of the otherwise unstable colloidal drug particles. This approach has advantages compared to surfactant-stabilized colloids in that no free stabilizers remain in solution (reduced toxicity), and the challenges associated with the synthesis of well-balanced amphiphiles are circumvented. The methodology was tested by trapping polyethylene glycol (PEG) at the surface of particles of a model polar drug-salbutamol sulfate. Colloidal probe microscopy is used to quantitatively demonstrate the trapping of the HFA-phile at the surface, and the ability of PEG in screening particle-particle cohesive interactions. Both physical stability and the corresponding aerosol characteristics are significantly improved compared to those of a commercial formulation. The fine particle fraction of PEG-coated salbutamol sulfate was observed to be 42% higher than that of Ventolin HFA. The formation of stable dispersions of terbutaline hemisulfate using the same approach, suggests this to be a generally applicable methodology to polar drugs.
Collapse
Affiliation(s)
- Libo Wu
- Department of Chemical Engineering and Materials Science, Wayne State University, Detroit, MI 48202, USA
| | | | | |
Collapse
|
19
|
Wu L, Bharatwaj B, Panyam J, da Rocha SRP. Core-shell particles for the dispersion of small polar drugs and biomolecules in hydrofluoroalkane propellants. Pharm Res 2007; 25:289-301. [PMID: 17943419 DOI: 10.1007/s11095-007-9466-2] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2007] [Accepted: 10/01/2007] [Indexed: 11/25/2022]
Abstract
PURPOSE Demonstrate the applicability of a novel particle-based technology for the development of suspensions of small polar drugs and biomolecules in hydrofluoroalkane (HFA) propellants for pressurized metered-dose inhalers (pMDIs). MATERIALS AND METHODS Emulsification diffusion was used to prepare core-shell particles. The shell consisted of oligo(lactide) grafts attached onto a short chitosan backbone. The active drug was arrested within the particle core. Colloidal Probe Microscopy (CPM) was used to determine the cohesive forces between particles in a model HFA propellant. The aerosol characteristics of the formulations were determined using an Anderson Cascade Impactor (ACI). Cytotoxicity studies were performed on lung epithelial and alveolar type II cells. RESULTS CPM results indicate that particle cohesive forces in liquid HFA are significantly screened in the presence of the polymeric shell and correlate well with the physical stability of suspensions in propellant HFA. The proposed formulation showed little or no cytotoxic effects on both Calu-3 and A549 cells. CONCLUSIONS Core-shell particles with a shell containing the lactide moiety as the HFA-phile showed excellent dispersion stability and aerosol characteristics in HFA-based pMDIs. This is a general strategy that can be used for developing novel suspension pMDIs of both small polar drugs and large therapeutic molecules.
Collapse
Affiliation(s)
- Libo Wu
- Department of Chemical Engineering and Materials Science, Wayne State University, Detroit, Michigan, USA
| | | | | | | |
Collapse
|
20
|
Buttini F, Soltani A, Colombo P, Marriott C, Jones SA. Multilayer PVA adsorption onto hydrophobic drug substrates to engineer drug-rich microparticles. Eur J Pharm Sci 2007; 33:20-8. [PMID: 18023332 DOI: 10.1016/j.ejps.2007.09.008] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2007] [Revised: 08/03/2007] [Accepted: 09/14/2007] [Indexed: 11/19/2022]
Abstract
Despite the availability of numerous crystal engineering techniques, generating drug-rich microparticles with a predetermined size, morphology and crystallinity still represents a significant challenge. A microparticle manufacturing method has recently been developed that attempts to 'shield' the physicochemical properties of micronised drugs by the application of a microfine polymer coating. The aims of this study were to investigate the nature of the drug-polymer interactions and determine the effects of this manufacturing strategy upon release of the drug from the microparticles. The adsorption of poly(vinyl alcohol) (PVA) on the micronised hydrophobic drug surface was found to reach equilibrium between 23 and 27 h. The Freundlich isotherm model was shown to give the most accurate fit to the experimental data and thus multilayer adsorption was assumed. The adsorptive capacity (1/n) was specific to the substrate and PVA grade. An increase in the PVA (%) hydrolysis value caused 1/n to increase from 0.76 to 1.05 using budesonide and from 0.31 to 0.79 when betamethasone valerate (BMV) was used. Increasing the molecular weight of the adsorbing polymer caused a reduction in the strength of PVA-adsorbate interaction when budesonide was used as the substrate (from 0.76 to 0.59), whereas a three-fold increase (from 0.31 to 0.86) was achieved when the BMV substrate was employed. A proportion of the adsorbed polymer was shown to remain associated with the substrate during the spray-drying process and the polymer coating resulted in a significantly higher (p<0.05, ANOVA) amount of drug release in 60 min (ca. 100%) compared to budesonide alone.
Collapse
Affiliation(s)
- F Buttini
- Department of Pharmacy, University of Parma, Area delle Scienze, 43100 Parma, Italy
| | | | | | | | | |
Collapse
|